Merck & Co., Inc. $MRK Shares Sold by Diversify Wealth Management LLC

Diversify Wealth Management LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 63.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 13,731 shares of the company’s stock after selling 24,300 shares during the period. Diversify Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $1,133,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Brighton Jones LLC raised its stake in Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after purchasing an additional 3,941 shares during the period. Savvy Advisors Inc. raised its stake in shares of Merck & Co., Inc. by 12.1% during the second quarter. Savvy Advisors Inc. now owns 8,085 shares of the company’s stock valued at $640,000 after purchasing an additional 871 shares in the last quarter. IFG Advisory LLC lifted its holdings in Merck & Co., Inc. by 25.9% in the second quarter. IFG Advisory LLC now owns 24,941 shares of the company’s stock worth $1,974,000 after purchasing an additional 5,137 shares during the period. Finally, Creative Financial Designs Inc. ADV grew its position in Merck & Co., Inc. by 9.2% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 17,578 shares of the company’s stock valued at $1,391,000 after buying an additional 1,482 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Late‑stage data: WELIREG® (belzutifan) + LENVIMA® (lenvatinib) cut risk of progression or death by ~30% vs cabozantinib in previously treated advanced renal cell carcinoma — strengthens Merck’s portfolio and potential label/market expansion for belzutifan combos. WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
• Positive Sentiment: Adjuvant benefit: KEYTRUDA® (pembrolizumab) + WELIREG® showed a ~28% reduction in risk of recurrence or death vs KEYTRUDA alone in certain earlier‑stage RCC patients — could broaden adjuvant use and support longer‑term Keytruda revenue. KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
• Positive Sentiment: KEYTRUDA combos show survival gains: Final KEYNOTE‑B96 analysis reported significant overall survival improvement for KEYTRUDA + paclitaxel (± bevacizumab) in platinum‑resistant recurrent ovarian cancer — strengthens case for additional approvals/uses. KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
• Positive Sentiment: Neoadjuvant/adjuvant progress: KEYTRUDA + Padcev reduced event‑free survival events by 47% and deaths by 35% in cisplatin‑eligible muscle‑invasive bladder cancer — another high‑impact potential indication. KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive-Bladder-Cancer When-Given Before-and-After Surgery
• Positive Sentiment: Pipeline collaborations: Synthekine is testing its IL‑2 candidate STK‑012 with Keytruda and chemo in PD‑L1 negative NSCLC — external partnerships expand combo opportunities for Keytruda. Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
• Positive Sentiment: Analyst/coverage support: Royal Bank of Canada began coverage and publicly said Merck could return to growth sooner than the market expects — can lift sentiment and estimates. RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects
• Neutral Sentiment: Corporate restructure: Merck is reorganizing into Oncology and Specialty/Pharma & Infectious Diseases teams ahead of Keytruda’s patent cliff — strategic but execution and cost implications will determine investor reaction. Merck Reshapes Drug Business As Keytruda Era Nears Turning Point
• Negative Sentiment: Gardasil sales weakness: Merck notified layoffs of ~150 workers at a US Gardasil manufacturing site amid sluggish Gardasil sales — signals vaccine revenue pressure even as cost cuts are implemented. Merck to lay off around 150 employees at US site amid slump in Gardasil sales
• Negative Sentiment: Retail sentiment cooling: Coverage notes Reddit trader enthusiasm has faded recently — a minor headwind to retail‑driven momentum but unlikely to change fundamentals. Merck Stock Jumps But Reddit Traders Are Getting Cold Feet

Merck & Co., Inc. Trading Up 3.5%

Shares of NYSE:MRK opened at $123.45 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.44 and a current ratio of 1.54. The stock has a market capitalization of $305.22 billion, a price-to-earnings ratio of 16.96, a PEG ratio of 2.40 and a beta of 0.28. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a 50 day moving average price of $112.93 and a 200 day moving average price of $97.39.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. The firm’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be given a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, CEO Robert M. Davis sold 47,434 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total value of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares in the company, valued at $52,362,780.08. This trade represents a 9.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the sale, the executive vice president owned 160,174 shares in the company, valued at $19,368,240.08. This represents a 19.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 over the last three months. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on MRK. Bank of America boosted their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. The Goldman Sachs Group boosted their target price on Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. TD Cowen increased their price target on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Finally, Royal Bank Of Canada started coverage on Merck & Co., Inc. in a research note on Wednesday. They issued an “outperform” rating and a $142.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $125.88.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.